Cagrilintide

Cagri, NNC0174-0833, AM833, "the amylin, " component of CagriSema (with semaglutide)

Checked Oct 28, 2026

The short answer

Proven in humans for weight loss and appetite suppression in adults with overweight or obesity

Grade A for weight loss, result worked: the 26-week Phase 2 trial and the cagrilintide-alone arm of the 68-week REDEFINE 1 trial both beat placebo.

Approved?: Not approved for any use.
Safety: B, characterized: Nausea and other stomach effects are common (nausea 20% to 47% across Phase 2 doses vs 18% on placebo) and a dedicated heart-rhythm study found no clinically relevant QTc effect, but there is no long-term monotherapy safety record.

The full answer: what it is for, the dose, the units

What people take it for: People take it to lower appetite and body weight. It is a once-weekly amylin-receptor drug from Novo Nordisk that is still investigational on its own.

Does it work for weight loss and appetite suppression in adults with overweight or obesity? A, proven in humans. Result: worked.

Grade A for weight loss, result worked: the 26-week Phase 2 trial and the cagrilintide-alone arm of the 68-week REDEFINE 1 trial both beat placebo. Most of the 20%+ headlines come from the combination with semaglutide, not cagrilintide alone.

No approval for any use.

Safety: B, characterized. Nausea and other stomach effects are common (nausea 20% to 47% across Phase 2 doses vs 18% on placebo) and a dedicated heart-rhythm study found no clinically relevant QTc effect, but there is no long-term monotherapy safety record.

Do not use if: Not for pregnancy/breastfeeding.

Could it be placebo? Trials for this use beat placebo on weight loss, so the effect is not placebo; gray-market powder is a different, unverified product.

The dose people use, and the units to draw

Trials gave 0.3 to 4.5 mg once weekly under the skin, and the Phase 3 monotherapy dose was 2.4 mg weekly after a step-up; no approved or independently verified self-use dose exists.

Source	Dose	How often and how	Who it was for	Link
Lau et al., Lancet 2021 (Phase 2, NCT03856047)	2.4 mgUse this dose	Once weekly, subcutaneous, 26 weeks; started at 0.6 mg and stepped up every 2 weeks to the final dose	906 randomised adults with overweight or obesity, no diabetes (706 on cagrilintide); 9.7% weight loss at 26 weeks vs 3.0% placebo	Methods (Procedures); Table 2
Lau et al., Lancet 2021 (Phase 2, NCT03856047)	4.5 mg (highest dose tested)	Once weekly, subcutaneous, 26 weeks; same step-up every 2 weeks	Same trial; 10.8% weight loss at 26 weeks vs 9.0% for liraglutide 3.0 mg and 3.0% placebo	Abstract; Table 2
Lau et al., Lancet 2021 (Phase 2, NCT03856047)	0.3 mg (lowest dose tested)	Once weekly, subcutaneous, 26 weeks; started at 0.3 mg	Same trial; 6.0% weight loss at 26 weeks vs 3.0% placebo	Methods (Procedures); Table 2
REDEFINE 1 cagrilintide-alone arm (Garvey et al., NEJM 2025; NCT05567796)	2.4 mgUse this dose	Once weekly, subcutaneous, 68 weeks; registry lists a 16-week step-up then 52 weeks of maintenance	Adults with overweight or obesity, no diabetes, with lifestyle intervention; 302 randomised to cagrilintide alone	Abstract (arms and doses); ClinicalTrials.gov arms and interventions
Enebo et al., Lancet 2021 (Phase 1b with semaglutide)	0.16 to 4.5 mg	Once weekly, subcutaneous, escalated over 16 weeks, with semaglutide 2.4 mg	95 adults with BMI 27 to 39.9 exposed to treatment; this is a combination design, not monotherapy	Abstract
Gabe et al., Diabetes Obes Metab 2024 (thorough QT study, NCT05804162)	Escalated to 4.5 mg	Once weekly, subcutaneous	105 healthy participants; no clinically relevant QTc prolongation	Abstract

Trials gave 0.3 mg once weekly at the low end and 4.5 mg once weekly at the high end (Lau, Lancet 2021, Table 2), with 2.4 mg weekly as the Phase 3 monotherapy dose (Garvey, NEJM 2025; NCT05567796).

The earlier titration and vial-mixing figures had no named non-seller source; they are removed. Searches of Huberman Lab, Attia, Dr. Abud Bakri and Examine found no cagrilintide dose statement (Examine page could not be opened). No label exists because cagrilintide alone is not approved.

Reported by the named source, never prescribed by us.

How many units do I draw?

Use the calculator: concentration in mg per mL is vial mg divided by water mL, and units on a U-100 syringe are dose mg divided by concentration, times 100. Open the dose calculator

Why it might work

Subcutaneous injection → amylin receptor complex binding
Cagrilintide is a fatty-acid-modified
Area postrema and nucleus of the solitary tract signaling → satiety signal amplification
Amylin receptor activation in brainste
Hypothalamic melanocortin pathway engagement → energy-expenditure upregulation
Amylin is proposed to increase resting
Glucagon suppression and hepatic glucose regulation
Like native amylin
Combined with semaglutide → additive weight loss (CagriSema)
The combination (CagriSema

Assumed pathway, not shown in people.

Cagrilintide is a long-acting analog of amylin, a pancreatic beta-cell hormone co-secreted with insulin. It agonizes the amylin receptor family (AMY1/2/3, calcitonin receptor + RAMP complexes) and the calcitonin receptor itself, acting on hindbrain and hypothalamic (homeostatic and hedonic) centers to suppress appetite, on the stomach to slow gastric emptying, and on the pancreas to blunt postprandial glucagon. An N-terminal C20 fatty-acid (lipidation) drives reversible albumin binding for a ~7-8 day half-life. Because it is a late-stage investigational drug with structural (cryo-EM) and human PD data, the mechanism is established rather than merely assumed, unlike most gray-market peptides.

The trials, claim by claim

Cagrilintide monotherapy produces clinically meaningful weight loss in humans (9.7% at 2.4 mg, 10.8% at 4.5 mg over 26 weeks, versus 3.0% on placebo).

Result: worked

Phase 2 multicentre randomised double-blind placebo- and active-controlled dose-finding trial (Lau et al., The Lancet 2021; NCT03856047, 906 randomised including 706 on cagrilintide, 57 sites/10 countries).

PubMed: Once-weekly cagrilintide for weight management, phase 2 (Lau, Lancet 2021)

Cagrilintide + semaglutide (CagriSema) yields ~20%+ weight loss in Phase 3, exceeding either agent alone.

Result: worked

REDEFINE 1 Phase 3a, 68 wk, n=3,417, randomised with cagrilintide-alone and semaglutide-alone arms; reported 22.7% mean weight loss if everyone stayed on drug (20.4% counting everyone), 60% achieving >=20%. Published NEJM 2025.

PubMed: REDEFINE 1, coadministered cagrilintide and semaglutide (Garvey, NEJM 2025)

Status

Cagrilintide acts as an agonist at amylin receptors (AMY1/2/3) and the calcitonin receptor to reduce food intake.

Mechanistic/structural (cryo-EM) and human PD data; mechanism is established for an investigational drug rather than assumed. Amylin-analog class precedent (pramlintide) is FDA-approved.

Cagrilintide receptor mechanism (PubMed)

Half-life is ~7-8 days (159-195 h), supporting once-weekly dosing.

Result: worked

Phase 1 human PK studies (single/multiple ascending dose), Enebo et al., Lancet 2021 (phase 1b, 95 participants exposed to treatment) reported a half-life of 159 to 195 h.

PubMed: Cagrilintide with semaglutide, phase 1b (Enebo, Lancet 2021)

GI events (nausea, vomiting, constipation) are the dominant adverse effects but are mostly mild-moderate and transient; no clinically relevant QTc prolongation.

Result: worked

Pooled RCT safety data; dedicated thorough-QT study in healthy participants (Gabe et al., Diabetes Obes Metab 2024). Phase 2 nausea 20% to 47% across doses vs 18% on placebo (Lau 2021).

PubMed: Cagrilintide thorough QT study (Gabe, Diabetes Obes Metab 2024)

Status

Cagrilintide alone is FDA-approved for weight loss.

FALSE. No standalone approval exists. Novo Nordisk filed an NDA for the CagriSema COMBINATION (Dec 18, 2025); cagrilintide monotherapy remains investigational and is in dedicated Phase 3 trials (RENEW). FDA states cagrilintide cannot be used in compounding under federal law (page current as of Oct 1, 2026). Gray-market 'research only' powder is unapproved.

FDA: Concerns with unapproved GLP-1 drugs (current as of 2026-10-01)

In REDEFINE 1, cagrilintide 2.4 mg alone produced 11.5% weight loss versus 3.0% on placebo at 68 weeks counting everyone, and 11.8% versus 2.3% if everyone stayed on drug.

Result: worked

Phase 3 RCT arm; company-reported subanalysis (EASD 2025). The primary NEJM paper is cited by PMID.

PubMed: REDEFINE 1 (Garvey, NEJM 2025)

CagriSema did not show non-inferiority to tirzepatide 15 mg over 84 weeks in the open-label REDEFINE 4 trial (23.0% vs 25.5%, efficacy estimand).

Result: did not work

Company-announced topline of an open-label Phase 3 RCT (n=809); no paper found.

Novo Nordisk release, Sept 21, 2026

Risks and the label warnings

Adverse events

Dominant adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain. In the CagriSema arm GI events hit ~79.6% vs ~39.9% placebo; cagrilintide-alone nausea ran 20% to 47% across Phase 2 doses versus 18% on placebo, mostly during titration, usually mild-to-moderate and transient. Injection-site reactions (redness, swelling, soreness) reported. Treatment discontinuation for adverse events was 8.5% on CagriSema (REIMAGINE 2) and 1.0% for nausea alone on cagrilintide (REDEFINE 1). As an appetite suppressant it can cause near-total appetite loss if titrated too fast, risking under-eating and dehydration.

Contraindications

Not for pregnancy/breastfeeding. Caution with personal/family history of medullary thyroid carcinoma or MEN2 (class-level precaution for calcitonin-receptor-active agents). Pre-existing severe GI motility disease (gastroparesis). Stacking with GLP-1/GIP agonists multiplies GI burden and can deepen caloric restriction, the very thing the combination trials watched closely. Anyone with disordered-eating history. Gray-market product additionally carries contamination/mis-dosing risk independent of the molecule.

Theoretical concerns

Amylin/calcitonin-receptor agonism delays gastric emptying, caution with gastroparesis and a theoretical aspiration concern under anesthesia (mirrors the GLP-1 class). Rodent studies of long-acting amylin/calcitonin agents raise the usual C-cell/thyroid question for the receptor family, though human signal for cagrilintide specifically is not established. Aggressive appetite suppression can mask inadequate nutrition. Gallbladder/biliary events accompany rapid weight loss generally.

What nobody knows yet

The biggest unknown for a buyer is NOT the molecule's biology, that is well studied, but the IDENTITY AND PURITY of gray-market powder sold 'for research only.' No standalone long-term (multi-year) monotherapy safety dataset exists; nearly all late-stage data is for the combination with semaglutide. Pediatric, pregnancy, and renal data are limited. Real-world unsupervised dosing without titration support is uncharacterized.

What else could explain the result

Almost everyone runs cagrilintide ALONGSIDE a GLP-1 or GLP-1/GIP agent (semaglutide, tirzepatide, retatrutide), which makes solo attribution nearly impossible, the headline weight-loss numbers people cite (20%+) are the COMBINATION, not cagrilintide alone (~9-11%). Add caloric restriction, resistance training, stimulants/other appetite suppressants, and frequent simultaneous peptide stacks. Any 'it worked' anecdote is almost always a multi-drug regimen.

Is the vial what it says?

Cross-checked against PubMed (Phase 2 Lancet 2021, J Med Chem 2021 development paper, NEJM 2025 REDEFINE, Diabetes Obes Metab 2024 QT study), ClinicalTrials.gov registry (NCT03856047 Phase 2 start 2019-03-01; NCT05564104, NCT05804162 Phase 1), ADA 2025 presentations, and FDA warning-letter record. Trial efficacy/safety numbers (9.7%/10.8% monotherapy; ~22.7% combination; ~80% vs ~40% GI events) are consistent across independent secondary sources. Citations link to specific PubMed records where a paper exists.

Half-life and storage

Half-life: ~7-8 days (reported elimination half-life 159-195 hours in Phase 1 human PK), enabling once-weekly dosing.

Once mixed: Lyophilized powder: store cold, let vial reach room temperature 10-15 min before reconstituting (no heat/microwave). Add bacteriostatic water slowly down the vial wall, swirl gently, do NOT shake (peptide/foam damage). Refrigerate reconstituted solution at 2-8C, protect from light, use within ~28-30 days, do not freeze. Discard if cloudy, discolored, or particulate. (Gray-market powder identity/purity cannot be assumed regardless of careful handling.)

What I noticed, and what people report

What people report

Volume of reports: moderate. A real body of reports, fairly consistent.

Moderate-to-high and rising. Strong mainstream and clinical-press coverage (driven by CagriSema), plus an active gray-market/biohacker community (Reddit, forums, vendor reviews, peptide-info sites). Far more chatter than an obscure peptide, though much of it conflates cagrilintide-alone with the semaglutide combination.

Fairly consistent on the core experience: appetite suppression works, nausea during titration is the main complaint, solo weight loss is real but more modest than GLP-1/GIP agents. Divergence shows up on whether cagrilintide 'adds much' on top of a GLP-1 and on tolerability of fast titration.

Mixed. The high-credibility layer is unusually strong here, peer-reviewed RCTs and major-journal/conference data anchor the claims. The low-credibility layer is the usual gray-market/affiliate/vendor content (peptide-shop blogs, dosing-calculator sites) that should be discounted; many exist to sell powder. Weight the published trials, discount the vendor pages.

Users commonly report strong, sometimes 'switch-off' appetite suppression and early satiety, several describe forgetting to eat or having to force meals, especially if they escalated the dose too quickly (anecdote, not measured).
Nausea during titration is the near-universal complaint; most report it is worst in the first weeks of each dose step and settles over 2-4 weeks, with constipation also frequently mentioned (anecdote).
Stacked with semaglutide or tirzepatide, people perceive cagrilintide as 'adding satiety' or breaking a plateau; run solo, many feel weight loss is real but slower and less dramatic than a GLP-1/GIP (anecdote).
A recurring theme is uncertainty about gray-market product, buyers worry about vial purity, under/over-dosing, and reconstitution, and some report inconsistent effects they attribute to vendor quality rather than the molecule (anecdote).

Reports are anecdote, not proof.

Can you tell if it is working?

Trackable

Yes, the scale plus a waist tape is the validated primary readout; a DEXA can corroborate that the loss is fat, though a firm lean-sparing signature isn't established for cagrilintide alone.

Bloodwork

Partly measurableConfidence: Plausible

A lab moves, but it's noisy, indirect, or off-target, treat it as a hint, not proof.

Cagrilintide's amylin agonism produces a genuine, human-documented glycemic action (postprandial glucagon suppression, slowed gastric emptying) that registers on HbA1c, but its headline efficacy is appetite-driven weight loss, which no blood test measures. The blood signal is a metabolic co-benefit, not proof of the drug's primary action.

HbA1cHbA1c (glycated hemoglobin)

In a dysglycemic user, a real downward drift (cagrilintide monotherapy cut HbA1c ~0.9 percentage points over 32 wk in type 2 diabetics, Frias 2023). In a normoglycemic user the move is small and largely secondary to weight loss, so it supports rather than proves efficacy.

Amylin agonism directly suppresses postprandial glucagon and slows gastric emptying, blunting glucose excursions; reinforced by weight loss.

Draw baseline

before first dose, prior to any dose escalation

Retest

12 weeks (HbA1c reflects ~3 months of glycemia, so it needs the full window to register the change)

Read this before you spend on labs

Cagrilintide is an obesity/appetite drug, not a diabetes drug: the thing it actually does, reduce appetite and bodyweight, is tracked by a scale, not bloodwork. HbA1c is the one routine lab with a documented human shift on this compound, but it moves meaningfully only in dysglycemic users; in a non-diabetic user with a normal baseline the drop is small and largely secondary to weight loss. So bloodwork confirms a metabolic co-benefit rather than proving efficacy, which is why this is graded partial, not direct like the incretins. Best objective proof of efficacy is the scale.

Other ways to track it

Body compositionDirect readout

Smart scale (body weight) + tape waist circumference; BP cuff as a secondary metabolic readout

Body weight trends down and waist circumference narrows over weeks to months. Body weight was the exact primary endpoint the cagrilintide dose-finding trial was powered on, so a working dose shows a clear, sustained downward slope on the weekly-average scale rather than day-to-day noise.

Cagrilintide is a long-acting amylin analog that suppresses appetite and slows gastric emptying, cutting energy intake. Percent body-weight change is the directly measured primary efficacy outcome in its human trials, and waist circumference (a reported secondary) tracks the central/visceral fat that matters metabolically.

Baseline before first dose. Weigh 2-3x/week (track the weekly average, not single readings); measure waist every 2-4 weeks. Expect the trend to become unambiguous by 8-12 weeks.

DEXA scanIndirect / noisy

DEXA scan, total fat mass, lean/appendicular lean mass, and visceral adipose tissue (VAT)

In a responder, DEXA shows fat mass (including VAT) declining, which corroborates the scale and confirms the weight lost is predominantly fat. Treat it as confirmation of fat loss, not as independent proof of efficacy: it largely re-reports what the scale already shows. A clean lean-sparing signature for cagrilintide monotherapy is not robustly established in humans, so read the lean-mass number cautiously rather than as an expected drug hallmark.

DEXA is the standard accessible way to partition weight change into fat vs. lean and to localize the visceral compartment. Any effective weight agent will show fat-mass decline; the specific claim that cagrilintide preserves lean mass rests more on preclinical/analog data than on strong human DEXA evidence for the compound alone, so this modality corroborates rather than validates.

Baseline scan before starting, repeat at 3-6 months to allow enough fat-mass change to exceed scan precision.How to do it right

Bottom line

Cagrilintide is genuinely trackable as a weight agent, but on fewer channels than people often assume. The scale plus a waist tape is the validated primary readout (body weight was the trial's primary endpoint). A DEXA can corroborate that the loss is fat, though it mostly re-confirms the scale and the lean-sparing 'signature' is not firmly human-validated for cagrilintide alone, so it stays corroborating rather than direct. Three honest caveats: (1) real-world use is usually stacked with a GLP-1 (CagriSema), so weight/fat/waist changes can't cleanly attribute the effect to cagrilintide vs. the GLP-1 or diet; (2) the headline subjective effect, appetite suppression and early satiety, has no blood or objective test, so you're tracking downstream body-composition consequences, not the appetite effect itself; and (3) a CGM glucose readout was dropped: there's no human CGM validation for cagrilintide, any signal in a normoglycemic user is small and confounded by reduced food intake (and by the GLP-1 when stacked), so it reflects expected caloric-restriction physiology rather than a validated drug-specific efficacy endpoint.

Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data, bring your own numbers.

How to track it

History

First documented human use: Yes, controlled human trials exist and are extensive. Novo Nordisk ran first-in-human Phase 1 single/multiple-ascending-dose pharmacokinetic studies around 2018 (the 159 to 195 h half-life comes from the Phase 1b trial, Enebo et al., Lancet 2021). The pivotal Phase 2 dose-finding monotherapy trial (NCT03856047) began 2019-03-01 and was published in The Lancet (Dec 2021). This is the OPPOSITE of a typical gray-market peptide: the human-trial blank is filled, not empty. What does NOT exist is standalone regulatory approval: the only filing is for the CagriSema combination (December 2025), though Novo started dedicated cagrilintide Phase 3 trials (RENEW) in November 2025.

Heads up: FDA is reviewing cagrilintide only inside a combination, and has approved nothing

Novo Nordisk submitted a new drug application on December 18, 2025 for CagriSema, which is cagrilintide plus semaglutide together, for chronic weight management. As of November 2, 2026 we could not confirm FDA acceptance or a decision date from a primary source, and the FDA's drug database lists no CagriSema or cagrilintide product, so nothing is approved. Cagrilintide on its own has no FDA submission and is in phase 3 trials. A review of the combination is not approval of the single ingredient, and not evidence for what people buy as cagrilintide alone.

Novo Nordisk release of December 18, 2025 and the FDA drug database (openFDA, data updated October 30, 2026). Rechecked November 2, 2026.. Novo Nordisk, CagriSema submission, December 18, 2025

2021-07Development/medicinal-chemistry paper (Kruse et al., J Med Chem) and Phase 1b co-administration trial (with semaglutide) published in The Lancet; first-in-human PK work (~2018) summarized.
2019-03Phase 2 dose-finding monotherapy trial (NCT03856047) begins; 906 randomised across 10 countries (706 on cagrilintide).
2021-12Phase 2 monotherapy results published in The Lancet (Lau et al.), ~10.8% weight loss at 4.5 mg/26 wk.
2023Phase 1 special-population PK studies (hepatic impairment NCT05564104) and thorough-QT study (NCT05804162) conducted.
2025-06REDEFINE 1 & 2 Phase 3 results presented (ADA 2025) and published (NEJM 2025) for CagriSema combination.
2025FDA observed gray-market sellers illegally selling 'cagrilintide' to U.S. consumers (warning letter to a 'research use only' seller, Dec 2024).
2025-11Novo Nordisk starts dedicated cagrilintide monotherapy Phase 3 trials (RENEW 1 and 2).
2025-12Novo Nordisk files the CagriSema NDA (combination, not cagrilintide alone) on Dec 18, 2025; an FDA decision is expected in Q4 2026.
2026-02REDEFINE 4: CagriSema missed non-inferiority to tirzepatide 15 mg (23.0% vs 25.5%, efficacy estimand).
2026-06REIMAGINE 1 to 3 (type 2 diabetes) presented at ADA; in REIMAGINE 2 the cagrilintide-alone arm lost 8.4% vs 14.2% on CagriSema (efficacy estimand).
2026-09REIMAGINE 5 (CagriSema 12.4% vs tirzepatide 5 mg 9.1% in type 2 diabetes) and REDEFINE 9 (21.0% vs 2.0% placebo) reported.
2026-10FDA's page on unapproved GLP-1 drugs states cagrilintide cannot be used in compounding under federal law.

All sources

PubMed. Cagrilintide: A Long-Acting Amylin Analog (review, PMID 36883831)(Class/mechanism review tying cagrilintide to amylin biology and CagriSema.)
PubMed. Cagrilintide Phase 2 monotherapy weight management (Lau et al., Lancet 2021)(Pivotal dose-finding RCT; 9.7% (2.4 mg) / 10.8% (4.5 mg) at 26 wk; NCT03856047.)
PubMed. Cagrilintide + semaglutide REDEFINE 1 Phase 3 (Garvey, NEJM 2025)(Combination Phase 3 (22.7% weight loss if everyone stayed on drug, 20.4% counting everyone); includes a cagrilintide-alone arm.)
PubMed. REDEFINE 2 (Davies, NEJM 2025)(CagriSema Phase 3 in people with type 2 diabetes.)
PubMed. Cagrilintide with semaglutide, phase 1b (Enebo, Lancet 2021)(First co-administration trial of cagrilintide and semaglutide.)
PubMed. Cagrilintide pharmacokinetics / development (J Med Chem 2021)(Development paper (Kruse et al.): albumin-binding lipidation. The 159 to 195 h half-life is from Enebo et al., Lancet 2021 (PMID 33894838).)
PubMed. Cagrilintide thorough QT study (Gabe et al., Diabetes Obes Metab 2024)(No clinically relevant QTc prolongation in healthy participants.)
ClinicalTrials.gov. RENEW 1 cagrilintide Phase 3 (NCT07220642)(Dedicated cagrilintide monotherapy Phase 3 in obesity; RENEW 2 (obesity with type 2 diabetes) is NCT07220759. Also: Phase 2 NCT03856047, Phase 1 NCT05564104/NCT05804162.)
FDA. Concerns with unapproved GLP-1 drugs (current as of 2026-10-01)(States cagrilintide cannot be used in compounding under federal law and is not a component of an approved drug; FDA has warned 'research use only' sellers.)
Lau DCW et al. Lancet 2021;398(10317):2160-2172. PMID 34798060(dose table)
Lau DCW et al. Lancet 2021;398(10317):2160-2172. PMID 34798060(dose table)
Lau DCW et al. Lancet 2021;398(10317):2160-2172. PMID 34798060(dose table)
Garvey WT et al. N Engl J Med 2025. PMID 40544433 (abstract states 2.4 mg and arm sizes); schedule from ClinicalTrials.gov NCT05567796 arm descriptions(dose table)
Enebo LB et al. Lancet 2021;397(10286):1736-1748. PMID 33894838(dose table)
Gabe MBN et al. Diabetes Obes Metab 2024;26(12):5805-5811. PMID 39279639(dose table)

Not medical advice. Grades reflect the evidence as of the date above and will change as data arrives. Reports from users are anecdote, not proof. Talk to a licensed clinician before you act on anything here.